Synergy Pharmaceuticals (SGYP) Sets New 52-Week High and Low at $1.64

Synergy Pharmaceuticals (NASDAQ:SGYP) shares reached a new 52-week high and low on Tuesday . The company traded as low as $1.64 and last traded at $1.66, with a volume of 3167450 shares changing hands. The stock had previously closed at $1.74.

SGYP has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $10.00 price objective on shares of Synergy Pharmaceuticals in a research note on Thursday, January 25th. BidaskClub lowered shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, February 6th. Oppenheimer downgraded shares of Synergy Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, January 4th. Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Wednesday, February 28th. Finally, HC Wainwright set a $7.00 price target on shares of Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Monday, January 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. Synergy Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $8.08.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of -21.05, a quick ratio of 3.88 and a current ratio of 4.33. The firm has a market cap of $431.66, a P/E ratio of -1.63 and a beta of 1.17.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.03. Synergy Pharmaceuticals had a negative net margin of 1,333.76% and a negative return on equity of 652.66%. The firm had revenue of $9.40 million during the quarter, compared to the consensus estimate of $7.12 million. Synergy Pharmaceuticals’s revenue was up 840.0% on a year-over-year basis. equities analysts anticipate that Synergy Pharmaceuticals will post -0.53 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of SGYP. HBK Sorce Advisory LLC bought a new stake in shares of Synergy Pharmaceuticals during the 4th quarter worth $103,000. Sandy Spring Bank bought a new stake in shares of Synergy Pharmaceuticals during the 4th quarter worth $109,000. MetLife Investment Advisors LLC bought a new stake in shares of Synergy Pharmaceuticals during the 4th quarter worth $124,000. Lehman Financial Resources Inc. lifted its holdings in shares of Synergy Pharmaceuticals by 405.9% during the 4th quarter. Lehman Financial Resources Inc. now owns 68,300 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 54,800 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Synergy Pharmaceuticals by 354.8% during the 4th quarter. Teacher Retirement System of Texas now owns 83,552 shares of the biopharmaceutical company’s stock worth $186,000 after acquiring an additional 65,182 shares during the last quarter. 53.05% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Synergy Pharmaceuticals (SGYP) Sets New 52-Week High and Low at $1.64” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/24/synergy-pharmaceuticals-sgyp-sets-new-52-week-high-and-low-at-1-64.html.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply